<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00629083</url>
  </required_header>
  <id_info>
    <org_study_id>CONSUI-US01</org_study_id>
    <nct_id>NCT00629083</nct_id>
  </id_info>
  <brief_title>Bulking Agents for the Treatment of Stress Urinary Incontinence in Females</brief_title>
  <official_title>A Single-Masked, Randomized, Multi-Center, 2-Arm Parallel Study Comparing the Safety and Effectiveness of Bulkamid® and Contigen® as Bulking Agents for the Treatment of Stress Urinary Incontinence in Females</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Contura</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regulatory and Clinical Research Institute (RCRI)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Contura</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to demonstrate the safety and effectiveness of Bulkamid®
      in the treatment of stress urinary incontinence (SUI) due to intrinsic sphincter deficiency
      (ISD) in adult women who have SUI or stress predominant mixed incontinence
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a single-masked, randomized, comparative multi-center, 2-arm parallel study
      intended to demonstrate the safety and effectiveness of Bulkamid® vs. Contigen® for the
      treatment of stress urinary incontinence (SUI)due to intrinsic sphincter deficiency (ISD) in
      adult women who have SUI or stress predominant mixed incontinence.

      Subjects will be randomized to receive either a polyacrylamide hydrogel (Bulkamid®)
      treatment, or a collagen treatment (Contigen®) using a 2:1 ratio and will be masked to the
      treatment. Screening baseline evaluations and collagen skin testing will be completed to
      determine eligible subjects. Following a negative skin test, a subject will be randomized and
      treated with Bulkamid® or the comparator device at the Treatment Visit.

      Subjects that are not continent will be considered for re-injection. A maximum of 3
      injections (initial + 2 re-injections) are allowed. After the last injection, subjects will
      attend the 3-Month, 6-Month and 12-Month Follow-up Visits plus a telephone contact at 9
      months.

      The study will record objective incontinence measurements, subject's perception of
      effectiveness and quality of life assessments. Adverse events will be recorded throughout the
      study.

      Each subject will be followed for 12 months from the last injection.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2008</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Effectiveness Endpoint</measure>
    <time_frame>12 Months</time_frame>
    <description>The number of subjects with at least a 50% reduction from baseline in both leakage, as measured by the 24h Pad Test, and daily number of incontinence episodes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of Participants With Device- and Procedure-related Serious Adverse Events Through 12 Months Follow-up.</measure>
    <time_frame>12 months</time_frame>
    <description>The number of participants with device- and procedure-related serious adverse events through 12 months follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>24hr Pad Test</measure>
    <time_frame>12 months</time_frame>
    <description>A measure of urine leaked during a 24-hour period on a known weight and quantity of pads at the 12-month endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting as a Responder</measure>
    <time_frame>12 months</time_frame>
    <description>At the 12-month primary endpoint follow-up visit, the subject was asked to provide her perception of treatment effectiveness by circling the most accurate description of her condition: cured/dry; much improved; improved; no change; worse. The response was dichotomized into responder or non-responder. A subject was classified as a responder if she reported that the treatment had cured, much improved, or improved her incontinence condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IQoL</measure>
    <time_frame>12 months</time_frame>
    <description>The IQoL is a validated instrument consisting of 22 questions grouped into three subscales: avoidance and limiting behaviors; psychosocial impacts, and social embarrassment. It is a subject self-reported quality-of-life measure specific to urinary problems that is used to assess the impact of urinary incontinence and urinary problems and their treatment. The subject scores each question on a scale of 1 to 5 with higher scores indicating more positive responses. The maximum score was 110 points and the minimum score was 22.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICIQ-UI Short Form</measure>
    <time_frame>12 months</time_frame>
    <description>The ICIQ-UI Short Form assesses the impact of symptoms of incontinence on quality of life and outcome of treatment. The questionnaire consists of three questions with a maximum score of 21 and a minimum score of zero (0). A lower score represents a decrease in the severity of symptoms (i.e., improvement).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Incontinence Episodes</measure>
    <time_frame>12 months</time_frame>
    <description>The total number of incontinence episodes experienced by the subject over three consecutive days.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">345</enrollment>
  <condition>Stress Urinary Incontinence</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bulkamid Hydrogel injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Contigen injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bulkamid</intervention_name>
    <description>Bulking injection with Bulkamid injection device</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Contigen</intervention_name>
    <description>Transurethral bulking injection</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be female 18 or more years of age.

          -  Females of childbearing potential or &lt;2 years post-menopausal must be using 2 forms of
             contraception.

          -  Suffer from SUI for at least 6 months.

          -  Have failed 2 previous non-invasive therapies for 3 months each.

          -  Have at least 3 incontinence episodes measured over 3 days.

          -  Have a baseline 24h pad test weight greater than or equal to 5 gm.

          -  Have VLPP ≤ 100 cm H2O.

          -  Have maximum cystometric capacity equal or higher than (≥) 250 mL.

          -  Have PVR urine ≤ 100 mL.

          -  Have a life expectancy of more than 2 years.

        Exclusion Criteria:

          -  Has urethral hypermobility &gt;30 deg.

          -  Has predominant urge incontinence.

          -  Has detrusor overactivity.

          -  Regularly or intermittently users of urethral catheter.

          -  Has had previous radiation treatment in the pelvic floor.

          -  Has had previous urethral surgery (i.e. fistula, diverticula)or urethral bulking.
             Failed sling or colposuspension procedure for at least 6 months may be included.

          -  Suffers from known polyuria.

          -  Has had three (3) or more culture-proven bacterial UTIs in the last 12 months.

          -  Has a current infection (urethritis, cystitis or vaginitis).

          -  Has unevaluated hematuria.

          -  Has a Prolapse Stage greater than II.

          -  Has a BMI&gt;35 kg/m2.

          -  Is taking pharmacological treatment for stress urinary incontinence, 4 weeks prior to
             screening.

          -  Is allergic to bovine collagen.

          -  Is known to suffer from severe allergies or anaphylaxis.

          -  Suffers from autoimmune diseases (e.e. connective tissue diseases) that could confound
             the treatment.

          -  Is currently taking or has taken systemic corticosteroids within the past 3 months.

          -  Currently has cancer or has a history of any cancer within the past 5 years (skin
             cancer with no evidence of skin malignancy, for at least 2 years, can be included).

          -  Currently suffering from unstable cardiovascular disease, cancer or uncontrolled
             diabetes.

          -  Has active herpes genitalis.

          -  Is currently participating in any other clinical trial or has participated in another
             clinical trial within 3 months of screening/baseline visit.

          -  Is pregnant, lactating or intending to become pregnant.

          -  Is not physically able to perform study procedure.

          -  Has a neurogenic bladder

          -  Had a vaginal delivery within 3 months prior to screening.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Silvia Garcia-Codony</last_name>
    <role>Study Director</role>
    <affiliation>Contura</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Incontinence Research Institute</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tower Urology - Institute for Continence - Cedars-Sinai Medical Office</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sherif Aboseif, MD</name>
      <address>
        <city>Oxnard</city>
        <state>California</state>
        <zip>93030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South California Permanente Medical Group</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford UniveritySchool of Medicine - Departmert of OB/GYN</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genitourinary Surgical Consultants</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Department of Urology</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami and Jackson Memorial Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specialists in Urology</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Discovery Clinical Trials</name>
      <address>
        <city>Winter Haven</city>
        <state>Florida</state>
        <zip>33881</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore University Health System</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LSU Health Science Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Urology</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Urogynecology</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McKay Urology</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Urology Group</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Institute for Research &amp; Education</name>
      <address>
        <city>West Chester</city>
        <state>Ohio</state>
        <zip>45069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Lukes Hospital and Health Network</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for the University of Pennsylvannia - Penn Center for Continence and Public Health: Division of Urology</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina - Department of Urology</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Clinics of North Texas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center at Dallas - Department of Urology</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanguard Urologic Research Foundation</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott &amp; White Memorial Hospital</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Vermont - The Continence Center</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virgina Mason Medical Center - Section of Urology and Renal Transplantation</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Can-Med Clinical Research, Inc.</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8T 5G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gary Steinhoff Clinical Research</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8V3N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>February 26, 2008</study_first_submitted>
  <study_first_submitted_qc>February 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2008</study_first_posted>
  <results_first_submitted>December 2, 2019</results_first_submitted>
  <results_first_submitted_qc>January 28, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 7, 2020</results_first_posted>
  <disposition_first_submitted>February 6, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>February 6, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 25, 2015</disposition_first_posted>
  <last_update_submitted>January 28, 2020</last_update_submitted>
  <last_update_submitted_qc>January 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SUI</keyword>
  <keyword>Bulkamid</keyword>
  <keyword>Urinary Incontinence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Incontinence, Stress</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The first subject was enrolled on June 4, 2008, and the last subject was enrolled on June 6, 2011. All participating study centers were in hospitals or clinics in the United States, Canada or France. The sites and investigators were qualified to treat stress urinary incontinence in women by experience and expertise.</recruitment_details>
      <pre_assignment_details>Pelvic Organ Prolapse Quantification, upright cystometry, Valsalva Leak Point Pressure, post-void residual measurement, daily number of incontinence episodes and a 24-hour pad test were completed prior to randomization to confirm eligibility in the trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Bulkamid Hydrogel</title>
          <description>Bulkamid hydrogel is a proprietary, cross-linked polyacrylamide hydrogel developed for urethral bulking. The hydrogel consists of a backbone of cross-linked polyacrylamide, with water molecules loosely bound to the polymer matrix.</description>
        </group>
        <group group_id="P2">
          <title>Contigen Injection</title>
          <description>Contigen is a sterile non-pyrogenic implantable device composed of highly purified bovine dermal collagen that was lightly crosslinked with glutaraldehyde and dispersed in phosphate-buffered physiological saline</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="228"/>
                <participants group_id="P2" count="117"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="200"/>
                <participants group_id="P2" count="103"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved out of country/state</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refused to return for 12 month visit</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>There was no difference in the analysis population from the assignment in participant flow.</population>
      <group_list>
        <group group_id="B1">
          <title>Bulkamid Hydrogel Injection</title>
          <description>Bulkamid: Bulking injection with Bulkamid injection device</description>
        </group>
        <group group_id="B2">
          <title>Contigen Injection</title>
          <description>Contigen: Transurethral bulking injection</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="228"/>
            <count group_id="B2" value="117"/>
            <count group_id="B3" value="345"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="228"/>
                    <count group_id="B2" value="117"/>
                    <count group_id="B3" value="345"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.0" spread="11.4"/>
                    <measurement group_id="B2" value="57.4" spread="14.3"/>
                    <measurement group_id="B3" value="57.8" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="228"/>
                    <count group_id="B2" value="117"/>
                    <count group_id="B3" value="345"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="228"/>
                    <measurement group_id="B2" value="117"/>
                    <measurement group_id="B3" value="345"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="228"/>
                    <count group_id="B2" value="117"/>
                    <count group_id="B3" value="345"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="206"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="312"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="228"/>
                    <count group_id="B2" value="117"/>
                    <count group_id="B3" value="345"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="214"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="323"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="228"/>
                    <count group_id="B2" value="117"/>
                    <count group_id="B3" value="345"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="228"/>
                    <count group_id="B2" value="117"/>
                    <count group_id="B3" value="345"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="197"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="228"/>
                    <count group_id="B2" value="117"/>
                    <count group_id="B3" value="345"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="228"/>
                    <count group_id="B2" value="117"/>
                    <count group_id="B3" value="345"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="185"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>24-hour Pad Test</title>
          <description>The 24-hour pad test is a standard test used to quantify the amount of urine leaked in a 24-hour period. The patient receives a known quantity and weight of dry pads at a clinic visit, wears them for 24 hours, stores the wet pads in a waterproof/airproof bag, and returns the used and unused pads to the clinic, where they are weighed and the amount of leaked urine (wet pads) is measured by weight.</description>
          <population>There were 345 subjects enrolled but not all of them provided baseline data for the 24-hour pad test. 223/228 test subjects and 112/117 control subjects provided baseline 24-hour pad test data.</population>
          <units>g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="223"/>
                    <count group_id="B2" value="112"/>
                    <count group_id="B3" value="335"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93.6" spread="127.8"/>
                    <measurement group_id="B2" value="115.4" spread="245.9"/>
                    <measurement group_id="B3" value="104.5" spread="186.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Daily Number of Incontinence Episodes</title>
          <units>number of daily episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="228"/>
                    <count group_id="B2" value="117"/>
                    <count group_id="B3" value="345"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.1" spread="2.8"/>
                    <measurement group_id="B2" value="3.5" spread="2.4"/>
                    <measurement group_id="B3" value="3.8" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Primary Effectiveness Endpoint</title>
        <description>The number of subjects with at least a 50% reduction from baseline in both leakage, as measured by the 24h Pad Test, and daily number of incontinence episodes</description>
        <time_frame>12 Months</time_frame>
        <population>Intent-to-treat (ITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Bulkamid Hydrogel Injection</title>
            <description>Bulkamid: Bulking injection with Bulkamid injection device</description>
          </group>
          <group group_id="O2">
            <title>Contigen Injection</title>
            <description>Contigen: Transurethral bulking injection</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Effectiveness Endpoint</title>
          <description>The number of subjects with at least a 50% reduction from baseline in both leakage, as measured by the 24h Pad Test, and daily number of incontinence episodes</description>
          <population>Intent-to-treat (ITT) population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Number of Participants With Device- and Procedure-related Serious Adverse Events Through 12 Months Follow-up.</title>
        <description>The number of participants with device- and procedure-related serious adverse events through 12 months follow-up.</description>
        <time_frame>12 months</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Bulkamid Hydrogel Injection</title>
            <description>Bulkamid: Bulking injection with Bulkamid injection device</description>
          </group>
          <group group_id="O2">
            <title>Contigen Injection</title>
            <description>Contigen: Transurethral bulking injection</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants With Device- and Procedure-related Serious Adverse Events Through 12 Months Follow-up.</title>
          <description>The number of participants with device- and procedure-related serious adverse events through 12 months follow-up.</description>
          <population>ITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>24hr Pad Test</title>
        <description>A measure of urine leaked during a 24-hour period on a known weight and quantity of pads at the 12-month endpoint.</description>
        <time_frame>12 months</time_frame>
        <population>Complete Case (CC): Randomized subjects with complete data for a specific endpoint at a particular time point (no imputed data).</population>
        <group_list>
          <group group_id="O1">
            <title>Bulkamid Hydrogel Injection</title>
            <description>Bulkamid: Bulking injection with Bulkamid injection device</description>
          </group>
          <group group_id="O2">
            <title>Contigen Injection</title>
            <description>Contigen: Transurethral bulking injection</description>
          </group>
        </group_list>
        <measure>
          <title>24hr Pad Test</title>
          <description>A measure of urine leaked during a 24-hour period on a known weight and quantity of pads at the 12-month endpoint.</description>
          <population>Complete Case (CC): Randomized subjects with complete data for a specific endpoint at a particular time point (no imputed data).</population>
          <units>grams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.0" spread="64.2"/>
                    <measurement group_id="O2" value="54.6" spread="120.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting as a Responder</title>
        <description>At the 12-month primary endpoint follow-up visit, the subject was asked to provide her perception of treatment effectiveness by circling the most accurate description of her condition: cured/dry; much improved; improved; no change; worse. The response was dichotomized into responder or non-responder. A subject was classified as a responder if she reported that the treatment had cured, much improved, or improved her incontinence condition.</description>
        <time_frame>12 months</time_frame>
        <population>Complete Case (CC): Randomized subjects with complete data for a specific endpoint at a particular time point (no imputed data).</population>
        <group_list>
          <group group_id="O1">
            <title>Bulkamid Hydrogel Injection</title>
            <description>Bulkamid: Bulking injection with Bulkamid injection device</description>
          </group>
          <group group_id="O2">
            <title>Contigen Injection</title>
            <description>Contigen: Transurethral bulking injection</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting as a Responder</title>
          <description>At the 12-month primary endpoint follow-up visit, the subject was asked to provide her perception of treatment effectiveness by circling the most accurate description of her condition: cured/dry; much improved; improved; no change; worse. The response was dichotomized into responder or non-responder. A subject was classified as a responder if she reported that the treatment had cured, much improved, or improved her incontinence condition.</description>
          <population>Complete Case (CC): Randomized subjects with complete data for a specific endpoint at a particular time point (no imputed data).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="187"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144"/>
                    <measurement group_id="O2" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IQoL</title>
        <description>The IQoL is a validated instrument consisting of 22 questions grouped into three subscales: avoidance and limiting behaviors; psychosocial impacts, and social embarrassment. It is a subject self-reported quality-of-life measure specific to urinary problems that is used to assess the impact of urinary incontinence and urinary problems and their treatment. The subject scores each question on a scale of 1 to 5 with higher scores indicating more positive responses. The maximum score was 110 points and the minimum score was 22.</description>
        <time_frame>12 months</time_frame>
        <population>Complete Case (CC): Randomized subjects with complete data for a specific endpoint at a particular time point (no imputed data).</population>
        <group_list>
          <group group_id="O1">
            <title>Bulkamid Hydrogel Injection</title>
            <description>Bulkamid: Bulking injection with Bulkamid injection device</description>
          </group>
          <group group_id="O2">
            <title>Contigen Injection</title>
            <description>Contigen: Transurethral bulking injection</description>
          </group>
        </group_list>
        <measure>
          <title>IQoL</title>
          <description>The IQoL is a validated instrument consisting of 22 questions grouped into three subscales: avoidance and limiting behaviors; psychosocial impacts, and social embarrassment. It is a subject self-reported quality-of-life measure specific to urinary problems that is used to assess the impact of urinary incontinence and urinary problems and their treatment. The subject scores each question on a scale of 1 to 5 with higher scores indicating more positive responses. The maximum score was 110 points and the minimum score was 22.</description>
          <population>Complete Case (CC): Randomized subjects with complete data for a specific endpoint at a particular time point (no imputed data).</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.3" spread="20.1"/>
                    <measurement group_id="O2" value="75.2" spread="23.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ICIQ-UI Short Form</title>
        <description>The ICIQ-UI Short Form assesses the impact of symptoms of incontinence on quality of life and outcome of treatment. The questionnaire consists of three questions with a maximum score of 21 and a minimum score of zero (0). A lower score represents a decrease in the severity of symptoms (i.e., improvement).</description>
        <time_frame>12 months</time_frame>
        <population>Complete Case (CC): Randomized subjects with complete data for a specific endpoint at a particular time point (no imputed data).</population>
        <group_list>
          <group group_id="O1">
            <title>Bulkamid Hydrogel Injection</title>
            <description>Bulkamid: Bulking injection with Bulkamid injection device</description>
          </group>
          <group group_id="O2">
            <title>Contigen Injection</title>
            <description>Contigen: Transurethral bulking injection</description>
          </group>
        </group_list>
        <measure>
          <title>ICIQ-UI Short Form</title>
          <description>The ICIQ-UI Short Form assesses the impact of symptoms of incontinence on quality of life and outcome of treatment. The questionnaire consists of three questions with a maximum score of 21 and a minimum score of zero (0). A lower score represents a decrease in the severity of symptoms (i.e., improvement).</description>
          <population>Complete Case (CC): Randomized subjects with complete data for a specific endpoint at a particular time point (no imputed data).</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
                <count group_id="O2" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" spread="4.9"/>
                    <measurement group_id="O2" value="7.9" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Incontinence Episodes</title>
        <description>The total number of incontinence episodes experienced by the subject over three consecutive days.</description>
        <time_frame>12 months</time_frame>
        <population>This analysis was performed on the Complete Case (CC) analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Treament</title>
            <description>Bulkamid Hydrogel injection
Bulkamid: Bulking injection with Bulkamid injection device</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Contigen injection
Contigen: Transurethral bulking injection</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Incontinence Episodes</title>
          <description>The total number of incontinence episodes experienced by the subject over three consecutive days.</description>
          <population>This analysis was performed on the Complete Case (CC) analysis set.</population>
          <units>Episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="1.7"/>
                    <measurement group_id="O2" value="1.4" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected from each participant through her study completion visit, typically at 12 months.</time_frame>
      <desc>The definition of adverse event and/or serious adverse event used to collect adverse event information do not differ from the clinicaltrials.gov definitions.</desc>
      <group_list>
        <group group_id="E1">
          <title>Bulkamid Hydrogel Injection</title>
          <description>Bulkamid: Bulking injection with Bulkamid injection device</description>
        </group>
        <group group_id="E2">
          <title>Contigen Injection</title>
          <description>Contigen: Transurethral bulking injection</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Study-specific</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="228"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ieva Ankorina-Stark, Ph D, Chief Scientific Officer</name_or_title>
      <organization>Contura International A/S</organization>
      <phone>011 45 8110 0900</phone>
      <email>ieva.ankorina-stark@contura.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

